Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review

Claudio Gambardella 1,2*, Chiara Offi 1, Guglielmo Clarizia 1, Roberto Maria Romano 1, Immacolata Cozzolino 3, Marco Montella 3, Rosa Maria Di Crescenzo 4, Massimo Mascolo 4, Angelo Cangiano 1, Sergio Di Martino 1, Giancarlo Candela 1 and Giovanni Docimo 1

Abstract

Background: Medullary thyroid carcinoma is a malignant uncommon and aggressive tumour of the parafollicular C cells. In about 75% of cases it is sporadic while, in case of RET mutation, it is associated to multiple endocrine neoplasia type 2 (25% of cases). The biochemical features of medullary thyroid carcinoma include the production of calcitonin and carcinoembryogenic antigen. The above-mentioned features are useful in the diagnostic process as well as in the follow up and in the prognostication of the disease. Even if calcitonin elevation is strongly associated to MTC, it can also be found increased in many pathological different conditions as pregnancy, lactation, C-cells hyperplasia, autoimmune thyroiditis, end stage renal disease, lung and prostate cancer and several neuroendocrine tumours. Major medullary thyroid tumours are usually connected to high doses of circulating calcitonin, in fact non-secretory variants have hardly been described.

Case presentation: We herein report the case of a 59 years old male, who had undergone total thyroidectomy for multinodular goiter with negative preoperative calcitonin, showing medullary thyroid carcinoma at definitive pathology. To the best of our knowledge, this is the first case documenting a non-secretory medullary thyroid carcinoma, with double negative markers at the time of diagnosis and at the relapse.

Conclusion: A Literature review underlining pathological hypothesis, differential diagnosis and alternative and innovative biomarkers to identify non-secretory medullary thyroid carcinoma was carried out.

Keywords: Medullary thyroid carcinoma, Thyroid cancer, Calcitonin, Carcinoembryogenic antigen

Background

Medullary thyroid carcinoma (MTC) is a malignant thyroid tumour originating from the parafollicular C cells. MTC is an uncommon disease, accounting around 1 to 10% of all thyroid cancers. It is characterised by a mean survival of 8.6 years, and a 10-years survival rates ranging from 69 to 89% [1]. MTC is the second most aggressive thyroidal cancer, after anaplastic carcinoma, accountable of the 14% of all thyroid cancers [1]. It may occur sporadically (75% of cases), otherwise in hereditary form (25% of cases), in case of RET proto-oncogene germline mutation, associated with multiple endocrine neoplasia type 2 (MEN 2) [2]. Sporadic MTC has a low growth rate, it is well differentiated, it generally shows up with local aggressiveness and it is frequently diagnosed at the stage of cervical nodal involvement [1]. Hereditary forms of MTC usually show locoregional invasion and lymph node metastases at the time of diagnosis [3].

Round cells producing amyloid substance, separated by fibrous septa and areas of microcalcification are the histological typical patterns of MTC. As biochemical characteristics, MTC are known for the secretion of calcitonin and carcinoembryogenic antigen (CEA) whose determination is important in the diagnostic phase as...
Calcitonin is a 32-amino acid monomeric peptide secreted by C-cells. In MTC, calcitonin is high at basal and after pentagastrin stimulation test and it is considered a highly sensitive and specific indicator of the disease. Early diagnosis of MTC is crucial because surgery is the only curative therapy. Therefore, in case of thyroid nodular disease, it is mandatory to include calcitonin evaluation in the routine work-up, in order to achieve an early MTC diagnosis [4]. Tumoral biomarkers evaluation can be controversial. MTC and NETs in general can in fact produce different markers such as procalcitonin, the precursor of calcitonin, neuron specific enolase (NSE) and chromogranin A (CgA). The same ones can be secreted in several neoplastic or benign conditions or they can be not produced at all, as it happens for millimetric MTC [5, 6]. Voluminous MTC are very rarely found non-secretory, in particular there seems to be a correlation between the calcitonin blood rates and the tumour’s dimensions, though very few calcitonin negative MTC have been described [7].

We herein report the case of a 59 years old male, who had undergone total thyroidectomy for multinodular goiter with negative preoperative calcitonin, showing a MTC at definitive pathology. Moreover, a comprehensive Literature review underlining pathological hypotheses, differential diagnosis, alternative and innovative biomarkers to early identify non-secretory MTC was carried out.

Case presentation
In June 2014, a 59 years old male with multinodular thyroid goiter was observed in our centre. Due to the presence of thyroidal disease, a hormonal evaluation was performed, showing a slight elevation of FT3 (5.19 pg/mL, normal value 3.5–4.5 pg/mL) and of Thyroglobulin (TG) (>300 ng/mL, normal value <50 ng/mL), with FT4, TSH, Ab anti TPO, Ab anti TG and Calcitonin (5.21 pg/mL, normal value <18.2 pg/mL) resulted in the normal range. Neck ultrasound (US) showed the presence of a large hypoechoic inhomogeneous nodule of 47 mm in the left lobe of thyroid gland, with a retrosternal extension. In the right lobe it was possible to identify only two small nodules, the largest being of 11 mm, with mixed echogenicity. A fine needle aspiration cytology (FNAC) of the left nodule and of the biggest one on the right lobe was performed, both concluding for Thyroid 2, negative for malignant cells, according to SIAPEC-IAP classification [8].

After 12 months, due to the worsening of the compressive symptomatology, the patient underwent a total thyroidectomy for a presumed retrosternal goiter at the General and Oncological Surgery Division of University of Campania “Luigi Vanvitelli” of Naples. After 2 days, according to the patient good clinical conditions, the patient was discharged. Despite the good performance status and the presence of no symptoms, definitive pathology showed the presence of a medullary carcinoma of 1.0 × 0.8 cm in the right lobe, while in the left lobe, a follicular adenoma of 6.0 × 4.0 cm, was detected. The right lobe of the thyroid revealed a poorly circumscribed, whitish nodule, measuring 1 cm in its largest diameter. The tumour showed a complex arrangement, which included solid, cord-like and insular areas set in a fibrous struma with relatively few amyloid deposits (Fig. 1a). The neoplastic cells were medium-sized plasmacytoid, round and spindle shaped cells, with abundant eosinophilic cytoplasm and nuclei with clumped chromatin and small nucleoli (Fig. 1b). Scattered mitoses were present. The neoplastic cells expressed cytokeratin 19 (Fig. 1c) and calcitonin (Fig. 1d); a weak reactivity for CD56 (Fig. 1e) and negativity for thyroglobulin (Fig. 1f) were also detected. A diagnosis of medullary thyroid carcinoma was made. Therefore, the patient was introduced to the standard follow up for medullary carcinoma with several and strict evaluations of calcitonin and CEA levels, and neck ultrasound without showing any sign of recurrence. The patient underwent genomic investigations without showing RET proto-oncogene mutation. Moreover, the patient underwent a total body 99Td scintigraphy in February 2016, in the attempt of precociously identifying a possible recurrence, without showing any areas of abnormal accumulation. In September 2016, during a routine follow-up performed by neck ultrasound, a nodule of 0.8 cm, suspicious for lymph node recurrence, was identified in the right thyroidal space without any elevation of calcitonin (<2.00 pg/ml) and CEA levels (1.49 ng/ml, normal value <10). The patient underwent a FNAC of the suspicious lesion, that showed at the morphological examination, on a haematic background, a dispersed neoplastic population, rarely arranged in loosely cohesive groups. The tumour cells were middle-sized cells, with an extremely variable aspect: spindle-shaped elements, epithelioid cells with round nuclei and scanty cytoplasm, sometimes with eccentric nuclei and a “plasmacytoid” appearance, or some voluminous cells with ample granular cytoplasms and pleomorphic and irregular nuclei. The chromatin was finely dispersed with inconspicuous nucleoli. The same morphology was evident on cell-block sections, but unfortunately, the immunocytochemistry investigations were negative for Calcitonin, thyroglobulin and PTH. Nevertheless, the morphological pattern was suggestive for a lymph-nodal recurrence of MTC.

Due to the uncertain diagnosis, the patient underwent a total body 18-FDG positron emitting tomography (PET), without showing any metabolic activity.
Despite the unconfirmed diagnosis, in February 2017, the patient underwent a central compartment neck dissection. Gross findings of the surgical specimen displayed in a single lymph node of 0.6 cm, the presence of metastasis of medullary thyroid carcinoma (Fig. 2). Similarly, the immunochemistry showed positivity for calcitonin and TTF-1, while thyroglobulin resulted negative.

The patient did not experience any further biochemical or imaging sign of suspicious recurrence at a 20 months follow-up.

**Discussion and conclusions**

We have described the rare case of a 59 years old male with MTC associated with undetectable calcitonin serum level. Only few similar cases have been previously described in Literature (Table 1). To the best of our knowledge, this is the first case documenting a non-secretory MTC, with double negative markers at the time of diagnosis and at the relapse.

Basal level of calcitonin above 100 pg/ml request further examinations, as it can help fetching an early diagnosis of MTC, whose importance is clear, as surgery is the only curative treatment for MTC (Table 1). Since elevated calcitonin serum rates can occur in many pathological conditions other than MTC, the differential diagnosis is provided by the pentagastrin stimulating test, showing an increase of calcitonin above 1000 pg/ml in MTC, as well as an associated elevation of CEA and CgA serum levels [9–12]. Calcitonin in FNAC washout fluids, evaluation of serum procalcitonin and calcium stimulation of calcitonin have also been proposed as specific diagnostic tests for MTC [13–15].
| Author      | Gender | Age | Size, mm | Preoperative calcitonin serum level | Calcitonin-HIC | Calcitonin-IHC | CGRP-IHC | CgA-IHC | Syn-IHC | TG-IHC | CEA-IHC | RET mutation | Follow-up | Relapse |
|-------------|--------|-----|----------|------------------------------------|----------------|----------------|----------|---------|---------|--------|---------|-------------|-----------|---------|
| Sobol       | F      | 82  | 20       | Normal range                       | Negative       | –              | –        | +       | NA      | NA     | +       | NA          | 6 month   | Lymph nodes, liver and bone |
| Schmid 1    | M      | 28  | NA       | NA                                 | Weak           | NA             | +        | +       | NA      | –      | –       | NA          | NA        | NA      |
| Schmid 2    | M      | 46  | NA       | NA                                 | Weak           | NA             | –        | +       | NA      | –      | –       | NA          | 19 month  | Lymph nodes |
| Schmid 3    | F      | 45  | NA       | NA                                 | Weak           | NA             | –        | –       | NA      | –      | –       | NA          | NA        | NA      |
| Schmid 4    | M      | 37  | NA       | NA                                 | Negative       | NA             | –        | +       | NA      | NA     | –       | NA          | NA        | NA      |
| Redding     | F      | 31  | 45       | 28                                 | Diffuse        | +              | NA       | NA      | +       | –      | –       | NA          | 43 month  | Negative |
| Bokhart     | F      | 50  | 20       | 0,8                                | Weak           | NA             | NA       | –       | +       | +     | +       | NA          | NA        | NA      |
| Sand        | F      | 73  | NA       | 5,3                                | Weak           | NA             | NA       | NA      | NA      | NA     | NA      | NA          | Deceased 6 weeks | NA |
| Dora        | M      | 43  | 20       | 4                                  | Diffuse        | +              | +        | –       | NA      | –      | –       | NA          | NA        | NA      |
| Wang        | M      | 68  | 70       | 38                                 | Weak           | +              | NA       | +       | NA      | –      | +       | NA          | 12 months | Negative |
| Giovannella | F      | 43  | 48       | 4,7                                | Diffuse        | +              | NA       | NA      | NA      | NA     | NA      | NA          | 24 months | NA      |
| Alapat      | F      | 16  | 30       | 4                                  | Diffuse        | +              | NA       | +       | NA      | –      | +       | NA          | 20 months | Negative |
| Chernyavsky | F      | 40  | 20       | 2,1                                | Negative       | –              | NA       | +       | +       | +     | NA      | +           | 12 months | Negative |
| Nakazawa    | M      | 76  | 60       | 22                                 | Weak           | NA             | NA       | +       | –       | NA     | NA      | 18 months   | Negative |
| Frank-Raue  | F      | 61  | 10       | 2,9                                | Weak           | +              | NA       | +       | +       | –      | +       | –           | 72 months | Negative |
| Frank-Raue  | M      | 70  | 80       | < 2                                | Weak           | +              | NA       | +       | +       | –      | +       | –           | 25 months | Pulmonary modes |
| Frank-Raue  | F      | 50  | 20       | 0,8                                | Weak           | +              | NA       | +       | +       | –      | +       | +           | 150 months | Lymph nodes |
| Frank-Raue  | M      | 47  | 30       | 2,6                                | Focal          | +              | NA       | +       | –       | +     | –       | –           | 18 months | Local tumor infiltration |
| Frank-Raue  | F      | 53  | 45       | NA                                 | Diffuse        | +              | NA       | +       | –       | +     | +       | +           | 21 months | Lymph node, bone, brain |
| Frank-Raue  | M      | 45  | 18       | 11                                 | Weak           | +              | NA       | +       | +       | –      | +       | +           | 21 months | Pulmonary |
| Frank-Raue  | F      | 45  | 55       | 1,5                                | Focal          | +              | NA       | +       | +       | –      | +       | +           | 36 months | Pulmonary failure |
| Ismi        | NA     | 57  | NA       | 5,6                                | Negative       | –              | NA       | +       | +       | –      | NA      | NA          | NA        | NA      |
| Author    | Gender | Age | Size, mm | Preoperative calcitonin serum level | Calcitonin-IHC | Calcitonin-IHC | CGRP-IHC | CgA-IHC | Syn-IHC | TG-IHC | CEA-IHC | RET mutation | Follow-up | Relapse |
|-----------|--------|-----|----------|------------------------------------|----------------|----------------|----------|---------|---------|--------|---------|-----------|-------------|-----------|---------|
| Brutsaert | F      | 49  | 26       | <2                                 | Diffuse        | NA             | NA       | NA      | NA      | NA     | NA      | +         | NA          | NA        | NA      |
| Kim       | M      | 34  | 10       | 3,7                                | Negative       | NA             | +        | +       | +       | +      | +       | -         | 12 months   | Negative  | NA      |
| Kasajima   | F      | 48  | 30       | 29                                 | Negative       | NA             | +        | +       | +       | NA     | NA      | -         | NA          | NA        | NA      |
| Samà 1    | M      | 60  | 38       | 7,8                                | Focal          | +              | NA       | +       | NA      | NA     | -       | -         | 120 months  | Negative  | NA      |
| Samà 2    | F      | 66  | NA       | 5                                  | NA             | NA             | NA       | NA      | NA      | NA     | NA      | NA        | 120 months  | Negative  | NA      |
| Samà 3    | M      | 53  | 12       | <10                                | Negative       | –              | NA       | –       | NA      | NA     | –       | +         | 36 months   | Negative  | NA      |
| Samà 4    | M      | 62  | 45       | 13                                 | Focal          | +              | NA       | +       | NA      | NA     | –       | -         | 36 months   | Negative  | NA      |
| Parmer    | F      | 74  | 20       | Normal range                       | Negative       | –              | NA       | +       | +       | –      | +       | NA        | NA          | NA        | NA      |
| Zhou 1    | F      | ≥30 | ≤10 mm   | 14 cases                          | Positive: 8 cases | + 8 cases      | NA       | +       | +       | –      | +       | NA        | NA          | NA        | NA      |
| Zhou 2    | M      | 8   | ≥30 vs 3 cases | < 30 vs 16 cases | Negative: 11 cases | - 11 cases | + 18 cases | - 1 case | + 19 cases | - 14 cases | + 4 cases | - 15 cases | NA in 15 cases - In 4 cases | NA        | NA      |
| Liu       | F      | 62  | 60       | 2                                  | Weak           | +              | NA       | NA      | NA      | NA     | NA      | NA        | NA          | NA        | NA      |
| Gambardella | M  | 59  | 10       | 5,21                              | Weak           | +              | NA       | +       | NA      | –      | NA      | –         | 20 months   | Laterocervical lymph-node |

MTC medullary thyroid carcinoma, PDMTC poorly differentiated MTC, Und undetectable, WDMTC well differentiated MTC, –, Not Available, TT total thyroidectomy, ET hemithyroidectomy, LYA lymphadenectomy
Zhou observed larger masses in the possibility, in this but characterized by high CgA serum level, hypothesizing infected by a MTC without calcitonin serum level elevation, expression of Ki67 and RET gene mutation [20].

Eases (1,75 years), the latter one characterized by over survival patients (12,5 years) or rapid progression diseases, which were also associated with higher rate of lymph nodes metastases, thus identifying tumour size as an independent survival indicator. Moreover, the study suggested a better oncological outcome for non-secretory MTC [20].

To date, only 50 cases of certified “atypical” MTC reported in 20 studies have been described in English Literature, and the current report is the 51th described case (Table 1). Sobol et al. described an 82 years old woman affected by a MTC without calcitonin serum level elevation, but characterized by high CgA serum level, hypothesizing the possibility, in this “chromograninoma”, of an altered co-regulation for genes of CgA and of hormone production [7]. Frank-Raue et al. reported 7 cases of non-secretory MTC, with a prevalence of the 0.83% in his large sporadic MTC population. Moreover, also the latter Authors identified a strong positivity for CgA, suggesting the role of CgA in the diagnosis of calcitonin negative MTC [19, 20].

The largest clinical series of non-secretory MTC was reported by Zhou et al., which identified 19 cases of calcitonin negative MTC among their 158 MTC treated patients with a surprisingly high prevalence of 12,02% [21]. Zhou observed larger masses in “typical” MTC group which were also associated with higher rate of lymph nodes metastases, thus identifying tumour size as an independent survival indicator. Moreover, the study suggested a better oncological outcome for non-secretory MTC [21]. Conversely, a bimodal behaviour was reported by Frank-Raue et al., which identified long-term survival patients (12,5 years) or rapid progression diseases (1,75 years), the latter one characterized by over expression of Ki67 and RET gene mutation [20].

Despite the low or undetectable calcitonin serum level of all patients with non-secretory MTC, at IHC in almost the half of the cases reported in Literature, the tumours presented diffuse or focal positivity for calcitonin and CEA, while a CgA positivity in 41 of the 43 tested patients was reported. High CgA serum levels are characteristic of NETs, which share the same neural crest ectoderm derivation similar to parafollicular C-cells with MTC. The correct diagnosis to discriminate between MTC and NETs, is often a challenge due to the presence of spindle-shaped or round cells in trabeicular arrangements with the presence of amyloid substance, moreover at IHC staining, both result positive for CgA, NSE and CEA. Therefore, the evaluation of calcitonin serum level and calcitonin at IHC staining are mandatory and diriment [20–23].

Another hard differential diagnosis is with the hyalinaising trabecular tumour, a rare thyroid neoplasm, which shares a similar histological pattern with MTC and a positive immunostaining for CgA, somatostatin and NSE. Conversely, it presents as characteristic and distinctive feature the thyroglobulin hyper-expression [24].

It is of paramount importance to understand the pathophysiology of the MTC to diagnose a calcitonin negative MTC at an early stage and arrive to a differential diagnosis. Several Authors advocated different hypotheses to explain this uncommon non-secretory behaviour. The hook effect, considered as a calcitonin assay interference, is the hypothesis proposed by different Authors [25, 26]. Hook effect or prozone effect occurs when, in a sample, a high level of analytes is present, resulting in a false negative value [27]. Redding et al. have supposed that the “conventional” antibodies would not recognized aberrant calcitonin or precursor molecules produced by abnormal secretory mechanisms and released by tumour cells [28–30]. Another theory appears to be the one proposed by Dora et al., either regarding the capacity of parafollicular tumour cells of synthesizing but not secreting calcitonin; or the total loss of the capacity to codify for it due to a dedifferentiation process [25]. It is also been suggested that some forms of neoplastic C-cells could result calcitonin non-secretive when actually secreting modified proportion of N-pro calcitonin, mature calcitonin and C-pro-calcitonin consequent to an alternative splicing of calcitonin gene related peptide (CGRP), when modern tests only measure monomeric calcitonin [20, 31]. Also, the non-secretory MTC DNA has been studied, calcitonin gene resulted to be mutated, being the reason of an absent or low calcitonin secretion [2]. Nakazawa et al. reached the same conclusion, hypothesizing that low calcitonin serum levels result from epigenetic or/and genetic CT/CGRP gene mutation [32]. Otherwise, since morphologically, MTC cells and thymus carcinoid tumour have
the same histological features, Schmid et al. proposed a thymic origin [32–34].

The most debated aspects in non-secretory MTC are diagnosis and follow-up. It is necessary to perform serial imaging tests, for example neck US and computed tomography (CT), liver and chest magnetic resonance (MRI), calcitonin, CEA and CgA serum level evaluations to identify a possible recurrence, even if the imaging methods do not allow the identification of small tumours [25–31]. Otherwise, Frank-Raue et al. have succeeded in demonstrating how selective venous catheterization can identify the 89% of occult persistent MTC [20]. Fluorine 18-fluorodeoxyglucose (18F-FDG) PET/TC has demonstrated its superiority over conventional imaging in identifying relapse or disease persistence, even if many authors do not consider it as a first choice method because of the high costs, the variable sensitivity ranging from 50 to 85% and its inability to detect smaller masses [25–36].

The calcitonin precursor (Procalcitonin) and CGRP have been studied as alternative biomarkers of non-secretory MTC. Procalcitonin in particular, resulted to be comparable to calcitonin in terms of sensitivity and specificity in identifying the primary tumour, the local extension and the eventual presence of metastases [34].

Brutsaert et al reported an elevation of preoperative serum Procalcitonin level in non-secretory MTC patients, with normal serum level after surgery, Procalcitonin is a stable protein with a half-life of 24 h in vivo [31]. With these promising features, Procalcitonin has the characteristics to replace calcitonin in the management of non-secretory MTC. The CALC-A gene that encodes for calcitonin can undergo alternative RNA splicing, producing CGRP. It can be secreted by nervous cells MTC cells and non neoplastic C-cell other than being associated to C-Cell hyperplasia when overexpressed and in co-expression of TTF-1 and PAX-8. An overexpression of CGRP was reported among the metastatic cases more than the primary localizations [31]. Though not fully studied yet, CGRP could be used to differentiate throrial NET from non-secretory MTC, as not expressed in follicular cells [35, 37–40].

Abbreviations

18-FDG/PET: 18-FDG positron emitting tomography; CEA: Carcinoembryogenic antigen; CgA: Chromogranin A; CT: Computed tomography; FNAC: Fine needle aspiration cytology; MEN 2: Multiple endocrine neoplasia type 2; MRI: Magnetic resonance; MTC: Medullary thyroid carcinoma; NETs: Neuroendocrine tumours; NSE: Neuron specific enolase; TG: Thyroglobulin; US: Ultrasound

Acknowledgements

N/A

Authors’ contributions

All authors have read and approved the manuscript. All authors contributed significantly to the present research and reviewed the entire manuscript. GamCl: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data; also participated substantially in the drafting and editing of the manuscript. OC: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data; also participated substantially in the drafting and editing of the manuscript. ClàGi: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. Ci: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. DCRM: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. DCM: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. DFC: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. DGi: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. MassMas: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. MarcMon: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. CA: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. DMs: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. CanGia: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data. Dg: Participated substantially in conception, design and execution of the study and in the analysis and interpretation of the data; also participated substantially in the drafting and editing of the manuscript.

Funding

No funding was obtained for this study.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. The datasets used and/or analysed during the current study are available from the Division of General Surgery, Second University of Naples, Via Pansini 5 80131 Naples, on reasonable request.

Ethics approval and consent to participate

Not applicable, data retrospectively obtained by clinical record.

Consent for publication

The patient gave written informed consent to publish.

Competing interests

The authors declare that they have no competing interests.

Author details

1Division of Thyroid Surgery - Department of Medical and Advanced Surgical Sciences, University of Campania "Luigi Vanvitelli", School of Medicine, Via Sergio Pansini, S, 80131 Naples, Italy. 2Department of Cardiothoracic Sciences, University of Campania "Luigi Vanvitelli", School of Medicine, Via Sergio Pansini S, 80131 Naples, Italy. 3Pathology Unit, Department of Mental and Physical Health and Preventive, Medicine University of Campania “Luigi Vanvitelli”, School of Medicine, Piazza Miraglia 2, 80138 Naples, Italy. 4Department of Advanced Biomedical Sciences, Pathology Section, University of Naples Federico II, Via Sergio Pansini S, 80131 Naples, Italy.

Received: 28 December 2018 Accepted: 24 September 2019

Published online: 16 October 2019

References

1. Docimo G, Tolone S, Conzo G, Limongelli P, Del Genio G, Parmeggiani D, De Palma M, Lupone G, Avenia N, Lucchini R, Monacelli M, Gulotta G, Scorino G, Pasquali D, Bellastella G, Esposito K, De Bellis A, Pezzolla A, Ruggiero R, Docimo L, A Gelatin-Thrombin Matrix Topical Hemostatic Agent (Floseal) in Combination With Harmonic Scalpel Is Effective in Patients Undergoing Total Thyroidectomy: A Prospective, Multicenter, Single-Blind, Randomized Controlled Trial. Surg Innov. 2016. https://doi.org/10.1177/1553350615599638.
2. Sand M, Gelios M, Sand D, Bechch FA, Bonhag G, Wolting E, Mann B. Serum calcitonin negative medullary thyroid carcinoma. World J Surg Oncol. 2006;497.
3. Conzo G, Docimo G, Pasquali D, Mauriello C, Gambardella C, Esposito D, Tartaglia E, Della Pietra C, Napolitano S, Rizzuto A, Santini L. Predictive value of nodal metastases on local recurrence in the management of

Gambardella et al. BMC Endocrine Disorders (2019) 19:103
18. Liu Y, Yuan L, Yang D, Jin Y. Serum calcitonin negative mixed medullary thyroid carcinoma. Eur J Endocrinol. 2006;154(6):677–683.

19. Conzo G, Tartaglia E, Avenia N, Calò PG, de Bellis A, Esposito K, Gambardella C, Iolo S, Pasquali D, Santini L, Sinisi MA, Sinisi AA, Testini M, Polistena A, Bellastella G. Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends. World J Surg Oncol. 2016. https://doi.org/10.1186/s12957-016-0879-4.

20. Frank-Rauë K, Machens A, Leidig-Bruchner G, Rondot S, Haag C, Schulze E, Lorenz A, Kreissl MC, Drahle H, Raue F, Schmid KW. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid. 2013;doi: https://doi.org/10.1089/thy.2012.0236.

21. Zhou Q, Yue S, Cheng Y, Jin J, Xu H. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin. Exp Toxicol Pathol. 2017. https://doi.org/10.1016/j.etp.2017.05.003.

22. Chenmaykovsky VS, Farghani S, Davidov T, Ma L, Barnard N, Amorosa LF, Trojský SZ. Calcitonin-negative neuroendocrine tumor of the thyroid: a distinct clinical entity. Thyroid. 2011. https://doi.org/10.1089/thy.2010.0299.

23. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):139–48.

24. Schmid KW, Meweswinkel F, Böcker W. Hyalinizing trabecular adenoma of the thyroid—morphology and differential diagnosis. Acta Med Austriaca. 1996, 23(1–2):65–8.

25. Dora JM, Canali MH, Capp C, Puñales MK, Vieira JG, Maia AL. Normal peroperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid. 2008. https://doi.org/10.1089/thy.2008.0291.

26. Leboeuf R, Langlois MF, Martin M, Afandii CE, Fink GD. “Hook effect” in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature. J Clin Endocrinol Metab. 2006;91(2):361–4.

27. Schiettecatte J, Anckaert E, Smitz J. Interferences in Immunoassays. In: Chi HU, editor. Advances in Immunoassay Technology. Brussels: Intech; 2012. p. 45–62.

28. Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid. 2000;10(9):19–22.

29. Wang TS, Ocal IT, Sosa JA, Cox H, Roman S. Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. Thyroid. 2008. https://doi.org/10.1089/thy.2007.0413.

30. Giovanna L, Crippa S, Cariani L. Serum calcitonin-negative medullary thyroid carcinoma: role of Ca and CEA as complementary markers. Int J Biol Markers. 2008;23(2):129–31.

31. Bratzaef EF, Gersten AJ, Tassler AB, Surks MI. Medullary thyroid cancer with undetectable serum calcitonin. J Clin Endocrinol Metab. 2015. doi: https://doi.org/10.1210/jc.2014-3095.

32. Nakazawa T, Cameselle-Teijeiro J, Vinagre J, Scacco P, Rousseau E, Eloy C, Sobrinho-Simões M. C-cell derived calcitonin-free neuroendocrine carcinoma of the thyroid: the diagnostic importance of CRGP immunoreactivity. Int J Surg Pathol. 2014. https://doi.org/10.1177/1066896914525228.

33. Schmid KW, Ensiinger C. “Atypical” medullary thyroid carcinoma with little or no calcitonin expression. Virchows Arch. 1998;433(3):209–15.

34. Schmid KW. Calcitonin-free medullary thyroid carcinoma: evidence for a neuroendocrine thyroid origin? J Pathol (Lond). 1997;181:32A.

35. Wells SA Jr, Asea SL, Drahle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JP, Facini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015. https://doi.org/10.1089/thy.2014.0335.

36. Costante G, Meringolo D, Durante C, Bianchi D, Noceira M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92(2):450–5.

37. Trimboli P, Giovanna L. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Clin Chem Lab Med. 2015. https://doi.org/10.1515/cclm-2015-0058.

38. Parmer M, Milan S, Torabi A. Calcitonin-negative neuroendocrine tumor of the thyroid. Int J Surg Pathol. 2017. https://doi.org/10.1097/ PSP.0000000000000789.

39. Bockhorn M, Filling A, Rewerk S, Liedke M, Dirsch O, Schmid KW, Böcker CE. Lack of elevated serum calcitonin in nonsecretory medullary thyroid carcinoma. J Surg Oncol. 2006;91(2):361–4.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.